Data Interoperability for Ambulatory Monitoring of Cardiovascular Disease: A Scientific Statement From the American Heart Association

on behalf of the American Heart Association Data Science and Precision Medicine Committee of the Council on Genomic and Precision Medicine and Council on Clinical Cardiology; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Wearable devices are increasingly used by a growing portion of the population to track health and illnesses. The data emerging from these devices can potentially transform health care. This requires an interoperability framework that enables the deployment of platforms, sensors, devices, and software applications within diverse health systems, aiming to facilitate innovation in preventing and treating cardiovascular disease. However, the current data ecosystem includes several noninteroperable systems that inhibit such objectives. The design of clinically meaningful systems for accessing and incorporating these data into clinical workflows requires strategies to ensure the quality of data and clinical content and patient and caregiver accessibility. This scientific statement aims to address the best practices, gaps, and challenges pertaining to data interoperability in this area, with considerations for (1) data integration and the scope of measures, (2) application of these data into clinical approaches/strategies, and (3) regulatory/ethical/legal issues.

Original languageEnglish (US)
Pages (from-to)e000095
JournalCirculation: Genomic and Precision Medicine
Volume17
Issue number3
DOIs
StatePublished - Jun 1 2024

Funding

AHA (17UNPG33840017)\u2020; The RICBAC Foundation\u2020; NIH (1 R01 HL135335-01, 1 R01 HL161008-01, 1 R21 HL137870-01, 1 R21EB026164-01 NHLBI (K23)\u2020; Doris Duke Charitable Foundation (Clinician Scientist Development Award 2022060)\u2020; Bristol Myers Squibb (research grant through Yale)\u2020 NIH/NHLBI (K23HL155970)\u2020; AHA (grant No. 856917)\u2020 NIH (R01 HL158071, P01HL158502)\u2020; American Heart Association (Atrial Fibrillation Strategically Focused Research Network grants 18SFRN34110067, 18SFRN34170013, 20SCG35490449)\u2020 Patient consent constitutes a mechanism to ensure that patients\u2019 interests are protected. Regulations produced and supported by the US Office of the National Coordinator for Health Information Technology govern specified actors or entities. However, data produced by these wearable devices may not be subject to existing laws and regulations. The Trusted Exchange Framework and Common Agreement was published to establish an infrastructure and governance model for data exchange across networks. Violating protections in the General Data Protection Regulation/Data Protection Act of 2018, Health Insurance Portability and Accountability Act of 1996, or 21st Century Cures Act may result in serious consequences, including substantial penalties and potentially criminal liability.

Keywords

  • AHA Scientific Statements
  • ambulatory care
  • cardiovascular diseases
  • electronic health records
  • International Classification of Diseases
  • wearable electronic devices

ASJC Scopus subject areas

  • Genetics
  • Cardiology and Cardiovascular Medicine
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'Data Interoperability for Ambulatory Monitoring of Cardiovascular Disease: A Scientific Statement From the American Heart Association'. Together they form a unique fingerprint.

Cite this